Licensing in ED Metuchen has recently acquired rights to Stendra (avanafil) and is seeking licensing opportunities in Canada, India, and South America, presenting a direct path for BD teams to pursue regional partnerships and co-promotion agreements.

Strategic Partnering The company emphasizes acquiring and commercializing clinically advantageous products with patent protection, indicating openness to in-licensing, co-development, or exclusive distribution deals to expand their portfolio.

Outsourced Manufacturing All products are manufactured by third-party producers, suggesting opportunities to offer manufacturing, supply chain optimization, or alternative CMOs that could reduce costs or improve timelines for future launches.

Small but Growth With a lean team and revenue in the low-to-mid single digits, Metuchen is positioned as agile and receptive to partnerships that accelerate commercialization, regional launches, and rapid revenue ramp-ups.

Tech & Compliance Utilizing Microsoft 365 and GoDaddy indicates basic but solid digital infrastructure; there may be upsell opportunities for advanced CRM, regulatory affairs systems, pharmacovigilance enhancements, or partner portal capabilities to streamline collaborations.